Feng Zhang 张锋

Feng Zhang 张锋

Investigator, McGovern Institute for Brain Research of MIT; 麻省理工学院神经科学教授,CRISPR技术先驱

Feng Zhang is a core institute member of the Broad Institute of MIT and Harvard, as well as an investigator at the McGovern Institute for Brain Research at MIT, the James and Patricia Poitras Professor in Neuroscience at MIT, and an associate professor at MIT, with joint appointments in the departments of Brain and Cognitive Sciences and Biological Engineering. Zhang is a bioengineer developing and applying novel molecular technologies for studying the molecular and genetic basis of diseases and providing treatment. He played a seminal role in developing optogenetics, a powerful technology for dissecting neural circuits using light. Since joining the Broad and McGovern institutes in January 2011, Zhang has pioneered the development of genome editing tools for use in eukaryotic cells – including human cells – from natural microbial CRISPR systems. Zhang leverages CRISPR and other methods to study the genetics and epigenetics of human diseases, especially complex disorders, such as psychiatric and neurological diseases, that are caused by multiple genetic and environmental risk factors and which are difficult to model using conventional methods. His lab’s tools, which he has made widely available, are also being used in the fields of immunology, clinical medicine, and cancer biology, among others. His long-term goal is to develop novel therapeutic strategies for disease treatment. Zhang received his A.B. in Chemistry and Physics from Harvard College and his Ph.D. in Chemistry from Stanford University.

张锋是哈佛-麻省理工Broad研究所的核心成员,同时也是麻省理工学院McGovern大脑研究所的研究员。他曾获得麻省理工神经科学系James and Patricia Poitras教授荣誉,并被大脑和认知科学与生物工程系共同任命为副教授。作为一名生物工程师,张锋在分子与基因疾病的研究与治疗中开发并应用新颖的分子技术。光遗传学是一门使用光解剖神经回路的强大技术,他在此领域的发展上起到至关重要的作用。自从在2011年一月加入Broad和McGovern研究所,张锋率先从天然微生物CRISPR系统中开发了用于真核细胞(包括人类细胞)的基因组编辑工具。他利用CRISPR系统与其它方法来研究人类疾病的基因遗传遗传与表观遗传学,特别针对于神经病学中因多种遗传和环境危险因素引起的精神及神经疾病等的复杂紊乱症状。传统的方法是非常难以模拟类似症状的。他实验室的工具被广泛的应用到免疫学、临床医学与癌症生物学中。张锋的长期目标是发展新的疾病治疗战略。他从哈佛大学取得化学与物理的学士学位,然后在斯坦福大学完成化学的博士学位。